A FDA Approval for Zytiga Before Chemotherapy – On the Horizon

On Wednesday, Johnson & Johnson said that the FDA will conduct a fast review of Zytiga as a treatment for men with advanced prostate cancer who have not received chemotherapy. The Food and Drug Administration has agreed to conduct a six-month review of Zytiga which should be completed in mid-December, 2012. According to representatives from [...]

More from the 2012 AACR Meeting – The Impact of Curcumin plus Docetaxil in Castrate Resistant Prostate Cancer

Curcumin is thought to have anti-cancer activity as well as to provide a synergistic effect with chemotherapy agents. Because of this Dr. Eloise Planchat of the Centre Jean Perrin, Division de Recherche Clinique, EA4231, Université d’Auvergne shared results from a prospective phase II study that assessed the impact of the combination of docetaxel (chemotherapy) plus [...]

Early Zytiga & Prednisone Trial For Metastatic Castration Resistant Prostate Cancer Is Un-blinded

In one of those situations when actual clinical practice precedes the normal drug development process a recent announcement from Janssen Research & Development, LLC (Johnson & Johnson) informs that they have un-blinded their Phase 3 study, COU-AA-302, which clearly demonstrates that Zytiga (abiraterone acetate), when taken with prednisone, is effective in treating both mildly symptomatic [...]

No Good Treatment for Men with Chemotherapy Induced Neuropathy

One of the common side effects reported from chemotherapy with Taxotere is neuropathy. In the trial used to receive FDA approval, TAX 327 which had 332 patients. In that trial the following percentage of men reported incidents of neuropathy: Neuropathy Sensory- Nerve damage causing tingling or pain, usually in feet or hands: Any Grade- 30.4% [...]

Fighting Infections while on Chemotherapy – Using Neulasta

Neulasta (Pegfilgrastim) is used to reduce the chance of infection in people who have certain cancers and are also receiving chemotherapy medications, including taxotere for men being treated for advanced prostate cancer. Chemotherapy is designed to kill fast growing cells. However, it can’t tell the difference between cancer cells and fast-growing healthy cells, including red [...]

Using Zytiga Prior to Chemotherapy, Is It A Good Idea?

It is interesting that Dr. S. Meyers just produced a video on the issue of using the newly approved drug Zytiga (abiraterone acetate) prior to chemotherapy instead of post-chemotherapy. I find it interesting because like him, I have been receiving a number of questions about this same issue. […]

On the Horizon- Final Results of VENICE First-Line Hormone-Refractory Metastatic Prostate Cancer Trial Expected in 2012

Regeneron Pharmaceuticals, Inc. announced that the Phase 3 VENICE clinical trial evaluating the investigational agent Zaltrap (aflibercept) in the first-line treatment of men with castrate resistant prostate cancer will continue to completion as planned. They have not been asked to make any modifications due to efficacy or to safety concerns. This decision is based on [...]

My Friend Fred

My very dear friend Fred who is a 20+ year prostate cancer warrior recorded this video. He has been on chemotherapy this past year. Fred is an activist who has been fighting on behalf of all of us. Thank you, Fred. I just thought I would share his video at: See my friend Fred Joel [...]

Carboplatin – A 2nd line chemotherapy?

Carboplatin is a chemotherapy agent used for treatment of many types of cancer. Currently, it is approved by the Food & Drug Administration (FDA) for treating patients with ovarian and non-small cell lung cancer. However, some oncologists use carboplatin “off-label” for other cancers. Commonly, these “off-label” uses include testicular, stomach, and bladder cancers as well [...]

Go to Top